QUINTESSENTIAL-2
A Phase 3 Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-Refractory Multiple Myeloma
What's the purpose of the trial?
The goal of this clinical trial is to compare the efficacy of treatment with BMS-986393 to treatment with standard of care therapies in patients with relapsed/refractory multiple myeloma.
Accepting patients
Participating Centers
There are 12 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Arlocabtagene Autoleucel (Arlo-cel)
- Carfilzomib
- Cyclophosphamide
- Daratumumab
- Dexamethasone
- Fludarabine
- Pomalidomide
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.